Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GEHC
HOLDGE HealthCare Technologies Inc. · Healthcare · United States · $27.6B · Avg Vol: $312M/d
COMPANY DESCRIPTION
GE HealthCare Technologies Inc. is a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, providing a comprehensive portfolio including medical imaging, ultrasound, patient care solutions, and biopharmaceutical manufacturing technologies. The company's competitive moat is founded on its vast installed base, strong brand reputation, deep R&D capabilities, and critical role in improving patient outcomes worldwide. GE HealthCare is a market leader across multiple healthcare segments, leveraging its extensive global reach and technological expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.3B | 19.6B | 19.7B | 20.6B | 4.0% | 21.0B | 21.8B | 22.8B | 5.1% |
| EPS | 4.63 | 3.05 | 4.37 | 4.56 | -0.5% | 4.15 | 4.84 | 5.33 | 8.1% |
| Shares | 454.0M | 455.3M | 457.0M | 455.7M | +0.4% | 454.9M | — | — | — |
| Debt | 8.6B | 9.9B | 9.4B | 10.5B | 6.6% | 10.6B | — | — | — |
| Equity | 9.4B | 7.1B | 8.4B | 10.4B | 3.5% | — | — | — | — |
| Op CF | 2.1B | 2.1B | 2.0B | 2.0B | -2.0% | 2.0B | — | — | — |
| Inv CF | -398.0M | -558.0M | -914.0M | -1.0B | — | — | — | — | — |
| Fin CF | -822.0M | -478.0M | -573.0M | 617.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GEHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc.(you) | $27.6B | 58 | HOLD |
| BSX | Boston Scientific Corporation | $65.8B | 60 | HOLD |
| PEN | Penumbra, Inc. | $12.5B | 54 | HOLD |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
| DXCM | DexCom, Inc. | $27.6B | 82 | STRONG BUY |
| EW | Edwards Lifesciences Corporation | $47.6B | 72 | BUY |
| BIO | Bio-Rad Laboratories, Inc. | $8.4B | 62 | HOLD |
| STE | STERIS plc | $20.9B | 80 | STRONG BUY |
| PODD | Insulet Corporation | $11.3B | 47 | HOLD |
| SYK.DE | STRYKER CORP. R | $127.2B | 52 | HOLD |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.8%